NATHAN MCBRIDE: Open Payments
NPI 1114915741 · OGDEN, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,594 in 163 payments from 19 companies in 2025. Trend: 2023 $1,913 · 2024 $2,316 · 2025 $2,594
Food & beverage: $2,594
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 37 | $538 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $289 |
| Janssen Biotech, Inc. | 14 | $249 |
| PFIZER INC. | 30 | $189 |
| Celltrion USA Inc. | 8 | $171 |
| Aimmune Therapeutics, Inc. | 9 | $169 |
| Ardelyx, Inc. | 10 | $169 |
| GENZYME CORPORATION | 9 | $165 |
| Regeneron Healthcare Solutions, Inc. | 5 | $113 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $108 |
Products named: RINVOQ, ENTYVIO, DUPIXENT, TREMFYA, VEGZELMA, IBSRELA, SKYRIZI, XELJANZ.
Industry payments across UT — which companies pay providers there.
